Immuno-oncology company Nouscom disclosed on Monday that its Investigational New Drug (IND) application for the first phase 1 clinical trial of its lead candidate NOUS-209 has passed US Food and Drug Administration (FDA) approval.
According to the company, NOUS-209 is an off-the-shelf therapeutic cancer vaccine based on shared frame-shift neoantigens.
The company will now launch a phase 1 clinical trial of the therapeutic vaccine NOUS-209 for gastric, colorectal and gastro-esophageal junction Microsatellite Instable (MSI) cancers (tumours characterised by a defective DNA mismatch repair system) in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab.
Under the phase 1 trial, the company will enrol up to 30 patients across several US clinical centres in the the third quarter of 2019. Initial clinical data are expected in early 2020.
In conjunction, the primary objective of the study is to demonstrate safety and tolerability of the combination regimen, evaluate vaccine-induced immune responses, as well as the preliminary signs of anti-tumour activity in enrolled patients.
Based on preclinical data, NOUS-209 is expected to induce potent and broad CD8+ and CD4+ responses in humans, concluded the company.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine